Logo do repositório
 
Publicação

MCT1 is a new prognostic biomarker and its therapeutic inhibition boosts response to Temozolomide in human glioblastoma

2021-07-11Artigo de investigação Acesso aberto
Ver registo simples
dc.contributor.authorGonçalves, Vera Miranda
dc.contributor.authorGonçalves, Céline S.
dc.contributor.authorGranja, Sara
dc.contributor.authorCastro, Joana Vieira de
dc.contributor.authorReis, Rui M.
dc.contributor.authorCosta, Bruno M.
dc.contributor.authorBaltazar, Fátima
dc.contributor.authorGranja, Sara
dc.date.accessioned2026-01-15T14:42:21Z
dc.date.available2026-01-15T14:42:21Z
dc.date.issued2021-07-11
dc.description.abstractGlioblastoma, the brain tumour with highest prevalence and lethality, exhibits a characteristic glycolytic phenotype with increased lactate production. Recently, we reported a MCT1 overexpression in GBMs tumours, being associated to tumour growth and aggressiveness. Thus, we aimed to disclose the role of MCT1 in GBM prognosis and in vivo therapy response. Importantly, MCT1 overexpression is associated with poor prognosis of GBM. Moreover, MCT1 inhibition retards GBM tumour growth and boosts response to temozolomide treatment.eng
dc.description.sponsorshipNORTE-01-0145-FEDER-000039 and NORTE-01-0247-FEDER-045914
dc.identifier.citationMiranda-Gonçalves, V., Gonçalves, C. S., Granja, S., Vieira de Castro, J., Reis, R. M., Costa, B. M., & Baltazar, F. (2021). MCT1 Is a New Prognostic Biomarker and Its Therapeutic Inhibition Boosts Response to Temozolomide in Human Glioblastoma. Cancers, 13(14), 3468. https://doi.org/10.3390/cancers13143468
dc.identifier.doi10.3390/cancers13143468
dc.identifier.eissn2072-6694
dc.identifier.urihttp://hdl.handle.net/10400.22/31539
dc.language.isoeng
dc.peerreviewedyes
dc.publisherMDPI
dc.relationproject UIDB/50026/2020 and UIDP/50026/2020
dc.relation.hasversionhttps://www.mdpi.com/2072-6694/13/14/3468
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/
dc.subjectMonocarboxylate transporters
dc.subjectGlioblastoma
dc.subjectLactate
dc.subjectWarburg effect
dc.subjectPrognostic biomarker
dc.titleMCT1 is a new prognostic biomarker and its therapeutic inhibition boosts response to Temozolomide in human glioblastomaeng
dc.typeresearch article
dspace.entity.typePublication
oaire.citation.issue14
oaire.citation.titleCancers
oaire.citation.volume13
oaire.versionhttp://purl.org/coar/version/c_970fb48d4fbd8a85
person.familyNameGranja
person.givenNameSara
person.identifier.ciencia-idC41F-02E4-065E
person.identifier.orcid0000-0001-8717-6751
relation.isAuthorOfPublication06306a95-9c06-47c7-b2e5-5bbf757bec17
relation.isAuthorOfPublication.latestForDiscovery06306a95-9c06-47c7-b2e5-5bbf757bec17

Ficheiros

Principais
A mostrar 1 - 1 de 1
Miniatura
Nome:
ART_Sara Granja2.pdf
Tamanho:
1.92 MB
Formato:
Adobe Portable Document Format
Ver/Abrir
Licença
A mostrar 1 - 1 de 1
Miniatura indisponível
Nome:
license.txt
Tamanho:
4.03 KB
Formato:
Item-specific license agreed upon to submission
Descrição:
Ver/Abrir

Coleções

ESS - CISA - Artigos
ESS - APCT - Artigos